|
WO2001003690A1
(en)
*
|
1999-07-12 |
2001-01-18 |
Virginia Commonwealth University |
Novel vasodilator cannabinoid analogs
|
|
IL148244A0
(en)
*
|
2002-02-19 |
2002-09-12 |
Yissum Res Dev Co |
Anti-nausea and anti-vomiting activity of cannabidiol compounds
|
|
US10538373B2
(en)
|
2002-08-14 |
2020-01-21 |
Gw Pharma Limited |
Pharmaceutical formulation
|
|
US9084771B2
(en)
*
|
2007-05-17 |
2015-07-21 |
Sutter West Bay Hospitals |
Methods and compositions for treating cancer
|
|
GB2456183A
(en)
|
2008-01-04 |
2009-07-08 |
Gw Pharma Ltd |
Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
|
|
GB2471987B
(en)
|
2008-06-04 |
2012-02-22 |
Gw Pharma Ltd |
Anti-tumoural effects of cannabinoid combinations
|
|
GB2478595B
(en)
|
2010-03-12 |
2018-04-04 |
Gw Pharma Ltd |
Phytocannabinoids in the treatment of glioma
|
|
TWI583374B
(zh)
|
2010-03-30 |
2017-05-21 |
Ｇｗ伐瑪有限公司 |
使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
|
|
US10441617B2
(en)
|
2013-03-15 |
2019-10-15 |
Biotech Institute, Llc |
Breeding, production, processing and use of medical cannabis
|
|
GB2530001B
(en)
|
2014-06-17 |
2019-01-16 |
Gw Pharma Ltd |
Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
|
|
GB2527599A
(en)
|
2014-06-27 |
2015-12-30 |
Gw Pharma Ltd |
Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
|
|
GB2531282A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
GB2531278A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabidiol in the treatment of intractable epilepsy
|
|
GB2531280A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabidiol in the treatment of intractable epilepsy
|
|
GB2531281A
(en)
|
2014-10-14 |
2016-04-20 |
Gw Pharma Ltd |
Use of cannabidiol in the treatment of intractable epilepsy
|
|
MX395015B
(es)
|
2014-12-12 |
2025-03-24 |
Ojai Energetics Pbc |
Composiciones microencapsuladas de cannabinoides
|
|
GB2539472A
(en)
|
2015-06-17 |
2016-12-21 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
GB2541191A
(en)
|
2015-08-10 |
2017-02-15 |
Gw Pharma Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
GB2548873B
(en)
|
2016-03-31 |
2020-12-02 |
Gw Res Ltd |
Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
|
|
GB2551985B
(en)
|
2016-07-01 |
2019-01-30 |
Gw Res Ltd |
Novel formulation
|
|
GB2551987A
(en)
|
2016-07-01 |
2018-01-10 |
Gw Res Ltd |
Oral cannabinoid formulations
|
|
GB2551986A
(en)
|
2016-07-01 |
2018-01-10 |
Gw Res Ltd |
Parenteral formulations
|
|
GB2553139A
(en)
|
2016-08-25 |
2018-02-28 |
Gw Res Ltd |
Use of cannabinoids in the treatment of multiple myeloma
|
|
IL248149B
(en)
|
2016-09-29 |
2020-03-31 |
Garti Nissim |
Dilutable formulations of cannbinoids and processes for their preparation
|
|
GB2557921A
(en)
|
2016-12-16 |
2018-07-04 |
Gw Res Ltd |
Use of cannabinoids in the treatment of angelman syndrome
|
|
GB2559774B
(en)
|
2017-02-17 |
2021-09-29 |
Gw Res Ltd |
Oral cannabinoid formulations
|
|
WO2018205022A1
(en)
|
2017-05-08 |
2018-11-15 |
Inmed Pharmaceuticals Inc. |
Ocular drug delivery formulation
|
|
GB2564383B
(en)
|
2017-06-23 |
2021-04-21 |
Gw Res Ltd |
Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
|
|
GB201715919D0
(en)
|
2017-09-29 |
2017-11-15 |
Gw Res Ltd |
use of cannabinoids in the treatment of epilepsy
|
|
GB2568471B
(en)
|
2017-11-15 |
2022-04-13 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
GB2568929A
(en)
|
2017-12-01 |
2019-06-05 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
GB2569961B
(en)
|
2018-01-03 |
2021-12-22 |
Gw Res Ltd |
Pharmaceutical
|
|
GB2572125B
(en)
|
2018-01-03 |
2021-01-13 |
Gw Res Ltd |
Pharmaceutical
|
|
GB2572126B
(en)
|
2018-01-03 |
2021-01-13 |
Gw Res Ltd |
Pharmaceutical
|
|
GB2572737A
(en)
|
2018-01-24 |
2019-10-16 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
CA3091088A1
(en)
*
|
2018-02-13 |
2019-08-22 |
Beetlebung Pharma Ltd. |
Cannabinoid derivatives and conjugates and uses thereof
|
|
GB201806953D0
(en)
|
2018-04-27 |
2018-06-13 |
Gw Res Ltd |
Cannabidiol Preparations
|
|
WO2020069214A2
(en)
|
2018-09-26 |
2020-04-02 |
Demetrix, Inc. |
Optimized expression systems for producing cannabinoid synthase polypeptides, cannabinoids, and cannabinoid derivatives
|
|
GB2579179A
(en)
|
2018-11-21 |
2020-06-17 |
Gw Res Ltd |
Cannabidiol-type cannabinoid compound
|
|
GB2580881A
(en)
|
2018-11-30 |
2020-08-05 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
GB2580653A
(en)
|
2019-01-21 |
2020-07-29 |
Gw Res Ltd |
Use of cannabinoids in the treatment of comorbidities associated with epilepsy
|
|
GB2581517A
(en)
|
2019-02-22 |
2020-08-26 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
GB2581987B
(en)
|
2019-03-06 |
2021-11-17 |
Gw Res Ltd |
Use of cannabidiol in combination with antibiotics
|
|
CA3179235A1
(en)
*
|
2019-05-23 |
2020-11-26 |
Kare Chemical Technologies Inc. |
Catalytic cannabinoid processes and precursors
|
|
GB2584140A
(en)
|
2019-05-23 |
2020-11-25 |
Gw Res Ltd |
Use of cannabidiol in the treatment of epileptic spasms
|
|
GB2584341B
(en)
|
2019-05-31 |
2023-03-01 |
Gw Res Ltd |
Cannabinoid formulations
|
|
GB201910389D0
(en)
|
2019-07-19 |
2019-09-04 |
Gw Pharma Ltd |
Novel compounds, methods for their manufacture, and uses thereof
|
|
GB2586026A
(en)
|
2019-07-29 |
2021-02-03 |
Gw Res Ltd |
Use of cannabidol in the treatment of Dravet syndrome
|
|
GB2588576A
(en)
|
2019-08-27 |
2021-05-05 |
Gw Res Ltd |
Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
|
|
GB2589306A
(en)
|
2019-10-25 |
2021-06-02 |
Gw Res Ltd |
Use of cannabidiol preparations in the treatment of fragile X syndrome
|
|
GB2588460A
(en)
|
2019-10-25 |
2021-04-28 |
Gw Res Ltd |
Use of cannabidiol preparations in the treatment of temporal lobe epilepsy
|
|
GB201916846D0
(en)
|
2019-11-19 |
2020-01-01 |
Gw Res Ltd |
Cannabidiol-type cannabinoid compound
|
|
GB201916974D0
(en)
|
2019-11-21 |
2020-01-08 |
Gw Res Ltd |
Cannabidol-type cannabinoid compound
|
|
GB201916977D0
(en)
|
2019-11-21 |
2020-01-08 |
Gw Res Ltd |
Cannibidol-type cannabinoid compound
|
|
GB201918846D0
(en)
|
2019-12-19 |
2020-02-05 |
Gw Res Ltd |
Oral cannabinoid formulations
|
|
GB202002754D0
(en)
|
2020-02-27 |
2020-04-15 |
Gw Res Ltd |
Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
|
|
GB2597318A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597323A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597313A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597312A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597321A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597316A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597322A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597315A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597281A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to brain injury
|
|
GB2597309A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597285A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597317A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597306A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597301A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with herpes simplex virus
|
|
GB2600077A
(en)
|
2020-07-20 |
2022-04-27 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB2597279A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
|
|
GB2597308A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain
|
|
GB2597311A
(en)
|
2020-07-20 |
2022-01-26 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
GB202013765D0
(en)
|
2020-09-02 |
2020-10-14 |
Gw Res Ltd |
Method of preparing cannabinoids
|
|
GB202014250D0
(en)
|
2020-09-10 |
2020-10-28 |
Gw Res Ltd |
Use of cannabidivarin in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
|
|
US20220087951A1
(en)
|
2020-09-18 |
2022-03-24 |
GW Research Limited |
Use of cannabinoids in the treatment of epilepsy
|
|
GB2598922A
(en)
|
2020-09-18 |
2022-03-23 |
Gw Res Ltd |
Use of cannabinoids in the treatment of epilepsy
|
|
US11160757B1
(en)
|
2020-10-12 |
2021-11-02 |
GW Research Limited |
pH dependent release coated microparticle cannabinoid formulations
|
|
GB2601755A
(en)
|
2020-12-08 |
2022-06-15 |
Gw Res Ltd |
Use of cannabidiol in the treatment of seizures associated with epilepsy syndromes
|
|
GB2602019A
(en)
|
2020-12-15 |
2022-06-22 |
Gw Res Ltd |
Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
|
|
TW202237554A
(zh)
|
2020-12-15 |
2022-10-01 |
英商吉偉研究有限公司 |
新穎化合物、其製備方法及其用途
|
|
GB2602020A
(en)
|
2020-12-15 |
2022-06-22 |
Gw Res Ltd |
A method for evaluating the pro- or anti convulsive properties of test compounds
|
|
GB2606334A
(en)
|
2021-02-12 |
2022-11-09 |
Gw Res Ltd |
Use of cannabidivarin in the treatment of seizures associated with canine epilepsy
|
|
KR20240007921A
(ko)
|
2021-05-12 |
2024-01-17 |
지더블유 리서치 리미티드 |
레조르시놀, 이의 제조 방법, 및 이의 용도
|
|
ES3058168T3
(en)
|
2021-05-12 |
2026-03-09 |
Jazz Pharmaceuticals Research Uk Ltd |
Resorcinol derivative as a pharmaceutically active compound and method of preparation thereof
|
|
CN117295706A
(zh)
|
2021-05-12 |
2023-12-26 |
吉伟研究有限公司 |
用于治疗癫痫的大麻二酚-c4的衍生物
|
|
US11815187B2
(en)
|
2022-01-26 |
2023-11-14 |
Maag Germany Gmbh |
3-port valve
|